152 related articles for article (PubMed ID: 33206973)
1. Monocyte CD169 Expression as a Biomarker in the Early Diagnosis of Coronavirus Disease 2019.
Bedin AS; Makinson A; Picot MC; Mennechet F; Malergue F; Pisoni A; Nyiramigisha E; Montagnier L; Bollore K; Debiesse S; Morquin D; Veyrenche N; Renault C; Foulongne V; Bret C; Bourdin A; Le Moing V; Van de Perre P; Tuaillon E
J Infect Dis; 2021 Feb; 223(4):562-567. PubMed ID: 33206973
[TBL] [Abstract][Full Text] [Related]
2. Monocyte CD169 expression in COVID-19 patients upon intensive care unit admission.
Ortillon M; Coudereau R; Cour M; Rimmelé T; Godignon M; Gossez M; Yonis H; Argaud L; Lukaszewicz AC; Venet F; Monneret G
Cytometry A; 2021 May; 99(5):466-471. PubMed ID: 33547747
[TBL] [Abstract][Full Text] [Related]
3. CD169 and CD64 could help differentiate bacterial from CoVID-19 or other viral infections in the Emergency Department.
Bourgoin P; Soliveres T; Barbaresi A; Loundou A; Belkacem IA; Arnoux I; Bernot D; Loosveld M; Morange PE; Michelet P; Malergue F; Markarian T
Cytometry A; 2021 May; 99(5):435-445. PubMed ID: 33491921
[TBL] [Abstract][Full Text] [Related]
4. CD169 Defines Activated CD14
Affandi AJ; Olesek K; Grabowska J; Nijen Twilhaar MK; Rodríguez E; Saris A; Zwart ES; Nossent EJ; Kalay H; de Kok M; Kazemier G; Stöckl J; van den Eertwegh AJM; de Gruijl TD; Garcia-Vallejo JJ; Storm G; van Kooyk Y; den Haan JMM
Front Immunol; 2021; 12():697840. PubMed ID: 34394090
[TBL] [Abstract][Full Text] [Related]
5. CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity.
Doehn JM; Tabeling C; Biesen R; Saccomanno J; Madlung E; Pappe E; Gabriel F; Kurth F; Meisel C; Corman VM; Hanitsch LG; Treskatsch S; Heim K; Stegemann MS; Ruwwe-Glösenkamp C; Müller-Redetzky HC; Uhrig A; Somasundaram R; Spies C; von Bernuth H; Hofmann J; Drosten C; Suttorp N; Witzenrath M; Sander LE; Hübner RH
Infection; 2021 Aug; 49(4):757-762. PubMed ID: 33825125
[TBL] [Abstract][Full Text] [Related]
6. Clinical research assessment by flow cytometry of biomarkers for infectious stratification in an Emergency Department.
Bourgoin P; Soliveres T; Ahriz D; Arnoux I; Meisel C; Unterwalder N; Morange PE; Michelet P; Malergue F; Markarian T
Biomark Med; 2019 Nov; 13(16):1373-1386. PubMed ID: 31617736
[No Abstract] [Full Text] [Related]
7. Increased Expression of CD169 on Blood Monocytes and Its Regulation by Virus and CD8 T Cells in Macaque Models of HIV Infection and AIDS.
Kim WK; McGary CM; Holder GE; Filipowicz AR; Kim MM; Beydoun HA; Cai Y; Liu X; Sugimoto C; Kuroda MJ
AIDS Res Hum Retroviruses; 2015 Jul; 31(7):696-706. PubMed ID: 25891017
[TBL] [Abstract][Full Text] [Related]
8. A Higher Frequency of CD14+ CD169+ Monocytes/Macrophages in Patients with Colorectal Cancer.
Li C; Luo X; Lin Y; Tang X; Ling L; Wang L; Jiang Y
PLoS One; 2015; 10(10):e0141817. PubMed ID: 26509874
[TBL] [Abstract][Full Text] [Related]
9. Elevated circulating monocytes and monocyte activation in COVID-19 convalescent individuals.
Park J; Dean LS; Jiyarom B; Gangcuangco LM; Shah P; Awamura T; Ching LL; Nerurkar VR; Chow DC; Igno F; Shikuma CM; Devendra G
Front Immunol; 2023; 14():1151780. PubMed ID: 37077911
[TBL] [Abstract][Full Text] [Related]
10. Sialylation-dependent interaction between PD-L1 and CD169 promotes monocyte adhesion to endothelial cells.
Cai K; Chen Q; Shi D; Huang S; Wang C; Ai Z; Jiang J
Glycobiology; 2023 Apr; 33(3):215-224. PubMed ID: 36651496
[TBL] [Abstract][Full Text] [Related]
11. Role of the interferons in CD64 and CD169 expressions in whole blood: Relevance in the balance between viral- or bacterial-oriented immune responses.
Bourgoin P; Biéchelé G; Ait Belkacem I; Morange PE; Malergue F
Immun Inflamm Dis; 2020 Mar; 8(1):106-123. PubMed ID: 32031762
[TBL] [Abstract][Full Text] [Related]
12. SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus.
Stuckrad SLV; Klotsche J; Biesen R; Lieber M; Thumfart J; Meisel C; Unterwalder N; Kallinich T
Lupus; 2020 Dec; 29(14):1914-1925. PubMed ID: 33081587
[TBL] [Abstract][Full Text] [Related]
13. Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV-2 infection.
Roussel M; Ferrant J; Reizine F; Le Gallou S; Dulong J; Carl S; Lesouhaitier M; Gregoire M; Bescher N; Verdy C; Latour M; Bézier I; Cornic M; Vinit A; Monvoisin C; Sawitzki B; Leonard S; Paul S; Feuillard J; Jeannet R; Daix T; Tiwari VK; Tadié JM; Cogné M; Tarte K
Cell Rep Med; 2021 Jun; 2(6):100291. PubMed ID: 33977279
[TBL] [Abstract][Full Text] [Related]
14. Monocytes and Macrophages, Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis.
Boumaza A; Gay L; Mezouar S; Bestion E; Diallo AB; Michel M; Desnues B; Raoult D; La Scola B; Halfon P; Vitte J; Olive D; Mege JL
J Infect Dis; 2021 Aug; 224(3):395-406. PubMed ID: 33493287
[TBL] [Abstract][Full Text] [Related]
15. A distinct innate immune signature marks progression from mild to severe COVID-19.
Chevrier S; Zurbuchen Y; Cervia C; Adamo S; Raeber ME; de Souza N; Sivapatham S; Jacobs A; Bachli E; Rudiger A; Stüssi-Helbling M; Huber LC; Schaer DJ; Nilsson J; Boyman O; Bodenmiller B
Cell Rep Med; 2021 Jan; 2(1):100166. PubMed ID: 33521697
[TBL] [Abstract][Full Text] [Related]
16. A rapid, easy, and scalable whole blood monocyte CD169 assay for outpatient screening during SARS-CoV-2 outbreak, and potentially other emerging disease outbreaks.
Michel M; Malergue F; Ait Belkacem I; Bourgoin P; Morange PE; Arnoux I; Miloud T; Million M; Tissot-Dupont H; Mege JL; Vitte J; Busnel JM
SAGE Open Med; 2022; 10():20503121221115483. PubMed ID: 35959245
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of CD169, HLA-DR, and CD64 expression as predictive biomarkers of SARS-CoV2 outcome.
Gatti A; Fassini P; Mazzone A; Rusconi S; Brando B; Mistraletti G
J Anesth Analg Crit Care; 2023 Mar; 3(1):6. PubMed ID: 37386613
[TBL] [Abstract][Full Text] [Related]
18. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19.
Hottz ED; Azevedo-Quintanilha IG; Palhinha L; Teixeira L; Barreto EA; Pão CRR; Righy C; Franco S; Souza TML; Kurtz P; Bozza FA; Bozza PT
Blood; 2020 Sep; 136(11):1330-1341. PubMed ID: 32678428
[TBL] [Abstract][Full Text] [Related]
19. CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy.
Lende SSF; Pahus MH; Monrad I; Olesen R; Mahr AR; Vibholm LK; Østergaard L; Søgaard OS; Andersen AHF; Denton PW; Tolstrup M
Front Cell Infect Microbiol; 2022; 12():919097. PubMed ID: 35865810
[TBL] [Abstract][Full Text] [Related]
20. High CD169 Monocyte/Lymphocyte Ratio Reflects Immunophenotype Disruption and Oxygen Need in COVID-19 Patients.
Minutolo A; Petrone V; Fanelli M; Iannetta M; Giudice M; Ait Belkacem I; Zordan M; Vitale P; Rasi G; Sinibaldi-Vallebona P; Sarmati L; Andreoni M; Malergue F; Balestrieri E; Grelli S; Matteucci C
Pathogens; 2021 Dec; 10(12):. PubMed ID: 34959594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
